Table 3.
HRa | SE | P value | 95% CI |
||
---|---|---|---|---|---|
Distant recurrence-free survival | |||||
ER staining | |||||
1%–9% | Reference | ||||
≥10% | 0.7 | 0.06 | <0.001 | 0.6 | 0.8 |
Negative | 1.2 | 0.2 | 0.3 | 0.8 | 1.7 |
Recurrence-free survival | |||||
ER staining | |||||
1%–9% | Reference | ||||
≥10% | 0.7 | 0.06 | <0.001 | 0.6 | 0.8 |
Negative | 1.2 | 0.2 | 0.2 | 0.9 | 1.7 |
Overall survival | |||||
ER staining | |||||
1%–9% | Reference | ||||
≥10% | 0.8 | 0.06 | 0.002 | 0.7 | 0.9 |
Negative | 1.5 | 0.2 | 0.02 | 1.1 | 2.0 |
aStratified by tumor grade and clinical stage.
HR, hazard ratio; SE, standard error; CI, confidence interval.